RevMed executives said the pancreatic cancer oral medication was officially launched today and is priced at $39,800 per month.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.